These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39071106)

  • 21. Dynamics of biological markets with multiple biosimilar competitors in the United States.
    Mouslim MC; Socal MP; Trujillo AJ
    Expert Opin Biol Ther; 2024 Nov; 24(11):1271-1278. PubMed ID: 39378044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 25. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
    García-Goñi M; Río-Álvarez I; Carcedo D; Villacampa A
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33918795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease.
    McNicol M; Abdel-Rasoul M; McClinchie MG; Morris GA; Boyle B; Dotson JL; Michel HK; Maltz RM
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):644-652. PubMed ID: 38334232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv.
    MacDonald K; McBride A; Alrawashdh N; Abraham I
    J Med Econ; 2020 Dec; 23(12):1466-1476. PubMed ID: 33023360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
    Liu A; Xuan A; Socal M; Anderson G; Anderson KE
    J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projected US savings from biosimilars, 2021-2025.
    Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
    Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 Jul; 24(7):647-653. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
    Feng K; Russo M; Maini L; Kesselheim AS; Rome BN
    JAMA Health Forum; 2024 Mar; 5(3):e235429. PubMed ID: 38551589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect on Patients' Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization.
    Fenna J; Guirguis M; Ibrahim C; Shirvaikar N; Sandhu I; Ghosh S; Jenkins M
    Can J Hosp Pharm; 2021; 74(2):122-129. PubMed ID: 33896951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
    Barszczewska O; Piechota A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
    Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
    JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
    Li E; Lobaina E
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators.
    Maksabedian Hernandez EJ; Graf M; Portelli A; Shafrin J
    J Med Econ; 2022; 25(1):1118-1126. PubMed ID: 35965481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.